Issue 4, 2017

The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase

Abstract

The development of a series of novel 7-azabenzofurans exhibiting pan-genotype inhibition of HCV NS5B polymerase via binding to the primer grip site is presented. Many challenges, including poor oral bioavailability, high clearance, bioactivation, high human serum shift, and metabolic stability were encountered and overcome through SAR studies. This work culminated in the selection of BMS-986139 (43) as a preclinical candidate.

Graphical abstract: The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase

Supplementary files

Article information

Article type
Research Article
Submitted
15 Nov 2016
Accepted
20 Jan 2017
First published
08 Feb 2017

Med. Chem. Commun., 2017,8, 796-806

The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase

K. J. Eastman, K. Parcella, K. Yeung, K. A. Grant-Young, J. Zhu, T. Wang, Z. Zhang, Z. Yin, B. R. Beno, S. Sheriff, K. Kish, J. Tredup, A. G. Jardel, V. Halan, K. Ghosh, D. Parker, K. Mosure, H. Fang, Y. Wang, J. Lemm, X. Zhuo, U. Hanumegowda, K. Rigat, M. Donoso, M. Tuttle, T. Zvyaga, Z. Haarhoff, N. A. Meanwell, M. G. Soars, S. B. Roberts and J. F. Kadow, Med. Chem. Commun., 2017, 8, 796 DOI: 10.1039/C6MD00636A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements